Amphastar Pharmaceuticals, Inc.

AMPH Healthcare Drug Manufacturers Specialty & Generic

Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024.

Revenue
+8.22%
EPS
+134.2%
Free cash flow
−29.4%
Total debt
+0.57%

Quarter to September 2026, against a year earlier

27.59 0.43 −1.53%
Market cap
$1.2B
P/E
12.3×
Fwd P/E
12.8×
Dividend yield
—
F-score
6/9
Altman Z
2.54
Beneish M
−2.57
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 5 Nov
Piotroski F-Score

+8 more TTM periods

6 6 5 6
ROE
12.90% 10.39% 10.30% 12.44%
ROA
6.12% 4.84% 4.68% 5.86%
ROIC
7.88% 6.69% 6.57% 6.12%
Return on Tangible Assets
12.44% 10.20% 11.49% 13.48%
Average Days of Receivables
81.49 79.76 73.74 0.00
Free Cash Flow per Share
2.54 2.98 3.50 3.26
Free Cash Flow
118.83 135.19 152.89 139.02
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026